Nektar Therapeutics (NKTR)
(Delayed Data from NSDQ)
$1.32 USD
-0.03 (-2.22%)
Updated Apr 18, 2024 04:00 PM ET
After-Market: $1.30 -0.02 (-1.52%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Price, Consensus and EPS Surprise
NKTR 1.32 -0.03(-2.22%)
Will NKTR be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for NKTR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NKTR
Nektar (NKTR) Up 7.5% Since Last Earnings Report: Can It Continue?
Nektar (NKTR) Begins Phase IIb Study Rezpeg in Alopecia Areata
NKTR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Nektar (NKTR) Q4 Loss Wider Than Expected, Revenue Beat
Nektar Therapeutics (NKTR) Reports Q4 Loss, Tops Revenue Estimates
Will Nektar Therapeutics (NKTR) Report Negative Q4 Earnings? What You Should Know
Other News for NKTR
NKTR, VERU and EGIO among mid-day movers
12 Health Care Stocks Moving In Thursday's Intraday Session
Nektar Therapeutics Sees Something In The Data And Puts Its Drug To The Test
Biotech Alert: Searches spiking for these stocks today
Biotech's Lawsuit With Eli Lilly Might Catalyze Stock